ValuEngine upgraded shares of iCAD (NASDAQ:ICAD) from a strong sell rating to a sell rating in a research report report published on Thursday.
iCAD (ICAD) traded down $0.12 during trading hours on Thursday, reaching $3.88. 66,553 shares of the company’s stock were exchanged, compared to its average volume of 37,940. The company has a quick ratio of 1.67, a current ratio of 1.95 and a debt-to-equity ratio of 0.31. iCAD has a fifty-two week low of $3.13 and a fifty-two week high of $6.07.
iCAD (NASDAQ:ICAD) last posted its earnings results on Wednesday, November 8th. The technology company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01. iCAD had a negative net margin of 49.16% and a negative return on equity of 47.31%. The business had revenue of $7.00 million during the quarter, compared to the consensus estimate of $7.43 million. sell-side analysts forecast that iCAD will post -0.62 earnings per share for the current year.
Large investors have recently bought and sold shares of the business. Segall Bryant & Hamill LLC bought a new stake in iCAD in the 3rd quarter worth approximately $133,000. Dimensional Fund Advisors LP grew its position in iCAD by 165.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 89,043 shares of the technology company’s stock worth $394,000 after purchasing an additional 55,455 shares during the period. Vanguard Group Inc. grew its position in iCAD by 0.4% in the 2nd quarter. Vanguard Group Inc. now owns 456,377 shares of the technology company’s stock worth $1,912,000 after purchasing an additional 2,007 shares during the period. Finally, Argent Capital Management LLC grew its position in iCAD by 13.2% in the 2nd quarter. Argent Capital Management LLC now owns 713,650 shares of the technology company’s stock worth $2,990,000 after purchasing an additional 82,967 shares during the period. 21.98% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/07/icad-icad-rating-increased-to-sell-at-valuengine.html.
iCAD, Inc is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.